Search

Displaying results 2911 - 2920 of 10000 in total
  1. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of … In a global, prospective, controlled, multi-center Phase 2/3 open-label clinical trial, all patients responded to susoctocog alfa treatment within 24 hours [L1129].

    Synonyms: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
  2. Drug

    Amonafide

    go.drugbank.com/drugs/DB05022
    Investigational

    Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.

    Salts: Amonafide L-malateCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [L34490,L42065] Vutrisiran is commercially available as a conjugate of N-acetylgalactosamine (GalNAc), a residue that enables the delivery of siRNA to hepatocytes. … [L42065] This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene.

  4. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. … Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure.

    Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamideCategories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  5. Drug

    Sulfamerazine

    go.drugbank.com/drugs/DB01581
    ApprovedVet approvedWithdrawn

    A sulfanilamide that is used as an antibacterial agent.

    Synonyms: N-(4-Methyl-2-pyrimidyl)sulfanilamide, N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide
  6. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  7. Drug

    Flurazepam

    go.drugbank.com/drugs/DB00690
    ApprovedIllicit

    A benzodiazepine derivative used mainly as a hypnotic.

  8. Drug

    Cefditoren

    go.drugbank.com/drugs/DB01066
    Approved

    Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

  9. Drug

    Glibornuride

    go.drugbank.com/drugs/DB08962
    ApprovedWithdrawn

    Glibornuride is a sulfonylurea-type anti-diabetic drug.

    Categories: Drugs Used in Diabetes
  10. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation. … DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack.